ClinChoice Raises 150mm of Series E Funding, Strengthening Its Global Services Capabilities


PHILADELPHIA CREAM, July 4, 2022 /PRNewswire/ — Recently, ClinChoice announced the successful completion of its $150 million Series E funding round. The investment was led by Legend Capital and co-invested by Taikang Life Insurance, Sherpa Healthcare Partners and existing shareholders including Lilly Asia Ventures and Apricot Capital. Proceeds from the financing will be used to fund the company’s continued business expansion and innovative service offering around the world.

ClinChoice, your full-service clinical CRO partner.

As a full-service clinical-stage CRO, ClinChoice serves the global market by providing integrated one-stop clinical development services to emerging biopharma, medical device and consumer healthcare customers worldwide. ClinChoice has over 3,000 employees worldwide covering most drug development hotbeds in the United States, Chinaseveral countries in Europe and South East Asia. With over 25 years of high-quality services, ClinChoice has performed over 1,000 full-service Phase I-IV clinical projects and supported over 100 innovative drug registrations, designs and clinical developments. ClinChoice strictly adheres to GCP and ICH standards and has developed robust SOPs recognized by more than 50 major multinational companies, all of which have passed multiple inspections and audits by major regulatory agencies around the world.

According to ClinChoice Global President and CEO, Mr. Ling ZHEN“We thank the investors for their confidence in ClinChoice. This round of capital investment fully validates ClinChoice’s rapid growth and future potential in the clinical CRO space. With the new funding round, we will further enhance our product offering. innovative services and continue our expansion activities through organic growth and M&A, in order to better serve our customers worldwide.”

Dr. Hongbin ZHOU, Co-Chief Investment Officer of Legend Capitalsaid, “We would like to express our gratitude for placing your trust in Legend Capital and we are delighted to be part of ClinChoice, along with the management team and existing shareholders, including Lilly Asia Ventures, Goldman Sachs. We are very positive about the growth prospects of the CRO industry. As a fast-growing CRO, ClinChoice has built an excellent platform combining global expertise with deep know-how in key local markets, to support innovation. Going forward, we will work closely with the management team to enhance its existing business, attract industry talent and launch new strategic initiatives.”

About ClinChoice

ClinChoice is a global clinical CRO, providing high quality, one-stop integrated service offerings for new biopharmaceutical and medical device customers worldwide. Our service offerings cover clinical operation, project management, biostatistics, data management, biostatistical programming, regulatory affairs, medical affairs, feasibility research, HGRAC submission, clinical safety management, site management organization, natural medicine/traditional Chinese medicine and phase I clinical research, etc. Now, ClinChoice has over 3,000 employees worldwide covering most drug development hotbeds in the United States, Chinaseveral countries in Europe and South East Asia. Since its inception, ClinChoice has completed several rounds of financing, with investments from renowned institutional investors including Goldman Sachs, Lilly Asia Ventures and DFJ Dragon Fund.

About Legend Capital

In April 2001, Legend Capital was established as a fund manager under Legend Holdings, focusing on growth-stage venture capital and private equity investments. Since its inception, Legend Capital has adhered to internationally recognized standards to create best practices in fund management and operations. With a proven track record of over 20 years, it now has comprehensive experience in managing and operating funds and has built an extensive ecosystem of partners across the entire investment chain.

Legend Capital goes the extra mile by providing proactive, value-added services to help portfolio companies innovate. We are committed to promoting industrial progress and social development, while ensuring high returns in various fields.

Our vision is to become an investment company with global influence. We live and breathe our core value of pursuing wealth with integrity to fulfill our corporate social responsibility. In 2019, Legend Capital signed the United Nations-backed Principles for Responsible Investment (PRI), intended to make responsible investing a long-term strategy for practicing sustainable development and the philosophy of green finance.y.

Quote

Quote

Show original content to download multimedia:https://www.prnewswire.com/news-releases/clinchoice-raises-150-mm-series-e-round-financing-further-strengthening-its-global-services-capabilities-301580307.html

SOURCEClinChoice

Previous $300 million secured to move train tracks from Del Mar cliffs
Next Solar Encapsulation Materials Market Trends, Global Industry Growth, Historical Analysis, Size, Share, Emerging Drivers, Demands, Key Players, Emerging Technologies and Industry Potential to 2028